Biotech Stocks with High Momentum Scores
ByAinvest
Saturday, Sep 13, 2025 6:26 am ET1min read
CNTA--
DNTH--
KRRO--
Dianthus Therapeutics Inc. (DNTH) has seen a 90% surge in the past month due to positive Phase 2 trial results for its lead asset, claseprubart (DNTH103), in generalized myasthenia gravis. The stock's Momentum score has surged from 31.69 to 88.24 over the past 7 days. Korro Bio Inc. (KRRO) has soared in Benzinga’s Momentum rankings by 50.26 points, from 22.39 to 72.65, due to the company's recently secured Orphan Drug Designation for its lead RNA-editing therapy, KRRO-110. Centessa Pharmaceuticals PLC (CNTA) has seen a 48.75 point jump in its Momentum score, from 38.07 to 86.82, with a 42.85% spike over the past week alone.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet